Bortezomib does not adversely affect stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
G.L. Uy, N.M. Fisher, S.M. Devine, D.R. Adkins, M.H. Tomasson, T.A. Graubert, J.F. DiPersio, R. VijVolume:
11
Year:
2005
Language:
english
DOI:
10.1016/j.bbmt.2004.12.228
File:
PDF, 59 KB
english, 2005